| Popis: |
Objective: The aim of this study was to prospectively compare the effects of oral dydrogesterone and micronized vaginal progesterone (MVP) gel for luteal phase support on the pregnancy outcomes of intracytoplasmic sperm injection (ICSI) and embryo transfer (ET) cycles with controlled ovarian hyperstimulation using gonadotropin-releasing hormone in antagonists protocol.Materials and Methods: Women with infertility who attended the gynecology and obstetrics department of Meram Medical Faculty Hospital between January 2017 and January 2021 were evaluated. For the purpose of this research study, 301 patients who underwent ICSI-ET were divided into two groups. Micronized vaginal progesterone (Crinone 8% 90 mg gel with 1 time daily) was administered to 147 patients in the first group; and oral dydrogesterone (Duphaston 10 mg with 3 time daily), to 154 patients in the second group from the day of oocyte pick-up. On the twelfth day post-transfer , the ß-hCG and serum progesterone levels were measured, and the results were evaluated. A β-hCG value of ≥ 20 mIU/mL was considered to be a positive result. The rates of biochemical pregnancy, clinical abortion, clinical pregnancy, and ongoing pregnancy were compared between the two groups.Results: Among the women who underwent ICSI-ET, those who received vaginal progesterone gel and oral dydrogesterone on the day of oocyte retrieval showed similar serum progesterone levels and β-hCG positivity, biochemical pregnancy, clinical abortion, clinical pregnancy, and ongoing pregnancy rates. In terms of side effect profile, vaginal discharge and irritation complaints were found to be significantly lower in the oral progesterone group.Conclusion: The clinical results obtained from the patients who were given vaginal progesterone and oral dydrogesterone supplementation were similar. Oral progesterone support is an effective method that is more easily tolerated by patients and can be safely used for luteal phase support. |
